admin

The 33-year-old is the son of a hip-hop legend and a thrill-ride movie headliner, but more than anything else, he’s an all-around great hang…Read More

We already can’t wait to spend more time with Task Force M…Read More

The action superstar is back with Den of Thieves 2: Pantera, but he’s got several hits in his heart-pounding catalogue worth your time…Read More

Social media influencer Nelson Holland opens up about discovering his love for wildlife, and how he’s trying to expose others to the great outdoors…Read More

Discover huge bargains on a slew of gently used and open-box items…Read More

The average wait time to see a neurologist following an initial referral was just over a month for older adults, with nearly 1 in 5 patients waiting more than 3 months, a cross-sectional analysis of Medicare data showed. Wait times were not affected by the number of available neurologists…Read More

A new federal rule could force hospitals and doctors’ groups to boost health cybersecurity measures to better protect patients’ health information and prevent ransomware attacks. Some of the proposed requirements could be expensive for healthcare providers. The proposed rule, issued by the US Department of Health and Human Services (HHS) and published on January 6 […]

Clinicians generally shouldn’t use potassium-competitive acid blockers (P-CAB) as first-line therapy for acid-related conditions, nonerosive gastroesophageal reflux disease (GERD), or peptic ulcer disease, according to a recent clinical practice update from the American Gastroenterological Association (AGA). However, P-CABs are recommended in place of proton pump inhibitors (PPIs) for most patients with Helicobacter pylori and other […]

TOPLINE: Metronomic capecitabine combined with an aromatase inhibitor extends median progression-free survival to 20.9 months compared with 11.9 months for aromatase inhibitor alone in hormone receptor–positive breast cancer. The combination therapy demonstrates improved overall survival with tolerable safety profile, showing grade 3 adverse events in 15.1% of patients…Read More

TOPLINE: According to a secondary analysis of the 24- Month Myopia Outcome Study of Atropine in Children (MOSAIC) trial, 0.05% atropine eye drops were more effective in controlling myopia progression and axial elongation than placebo eye drops in children despite causing blurred vision and photophobia in some participants…Read More